Targeting CDK4/6 in patients with cancer

Shapiro, 2006, Cyclin-dependent kinase pathways as targets for cancer treatment, J Clin Oncol, 24, 1770, 10.1200/JCO.2005.03.7689 Ortega, 2002, Cyclin D-dependent kinases, INK4 inhibitors and cancer, Biochim Biophys Acta, 1602, 73 Malumbres, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, 9, 153, 10.1038/nrc2602 Grossel, 2006, From cell cycle to differentiation: an expanding role for cdk6, Cell Cycle, 5, 266, 10.4161/cc.5.3.2385 Baker, 2012, CDK4: a key player in the cell cycle, development, and cancer, Genes Cancer, 3, 658, 10.1177/1947601913478972 Paternot, 2010, Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase, 9, 689 Lange, 2011, Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer, Endocr Relat Cancer, 18, C19, 10.1530/ERC-11-0112 Cassier, 2014, Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program, J Clin Oncol, ASCO, 32 Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Geradts, 1996, High frequency of aberrant p16(INK4A) expression in human breast cancer, Am J Pathol, 149, 15 Musgrove, 2011, Cyclin D as a therapeutic target in cancer, Nat Rev Cancer, 11, 558, 10.1038/nrc3090 Lim, 2005, Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells, Proc Natl Acad Sci U S A, 102, 5156, 10.1073/pnas.0501203102 Young, 2014, Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines, Pigment Cell Melanoma Res, 27, 590, 10.1111/pcmr.12228 Reed, 1996, High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma, Cancer Res, 56, 3630 Molenaar, 2008, Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma, Cancer Res, 68, 2599, 10.1158/0008-5472.CAN-07-5032 Crago, 2011, Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma, Curr Opin Oncol, 23, 373, 10.1097/CCO.0b013e32834796e6 Singer, 2007, Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma, Cancer Res, 67, 6626, 10.1158/0008-5472.CAN-07-0584 Louis-Brennetot, 2011, The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors, Genes Chromosomes Cancer, 50, 896, 10.1002/gcc.20909 Zuo, 1996, Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma, Nat Genet, 12, 97, 10.1038/ng0196-97 Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024 Haluska, 1998, Molecular genetics of familial cutaneous melanoma, J Clin Oncol, 16, 670, 10.1200/JCO.1998.16.2.670 Potrony, 2014, Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling, J Am Acad Dermatol, 71, 888, 10.1016/j.jaad.2014.06.036 Dreyling, 2011, Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network, Leuk Lymphoma, 52, 2226, 10.3109/10428194.2011.600488 Pérez-Galán, 2011, Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era, Blood, 117, 26, 10.1182/blood-2010-04-189977 Fernandez, 2005, Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways, J Clin Oncol, 23, 6364, 10.1200/JCO.2005.05.019 Abou-Zeid, 2011, Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer, Scand J Clin Lab Invest, 71, 542, 10.3109/00365513.2011.590224 Jackson, 2009, Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors, Clin Cancer Res, 15, 1923, 10.1158/1078-0432.CCR-08-2091 Kuwahara, 2010, Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism, Cancer Res, 70, 1854, 10.1158/0008-5472.CAN-09-1922 Zhang, 2002, Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5, Mol Cell Biol, 22, 5975, 10.1128/MCB.22.16.5975-5988.2002 Wang, 2014, MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6, J Exp Clin Cancer Res, 33, 69, 10.1186/s13046-014-0069-6 Lin, 2012, Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells, FEBS Lett, 586, 442, 10.1016/j.febslet.2012.01.027 Roberts, 2012, Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy, J Natl Cancer Inst, 104, 476, 10.1093/jnci/djs002 Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy, Clin Cancer Res, 20, 3379, 10.1158/1078-0432.CCR-13-1551 Fry, 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol Cancer Ther, 3, 1427, 10.1158/1535-7163.1427.3.11 Dean, 2012, Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors, Cell Cycle, 11, 2756, 10.4161/cc.21195 Witkiewicz, 2014, CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models, Genes Cancer, 5, 261, 10.18632/genesandcancer.24 Gelbert, 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest New Drugs, 32, 825, 10.1007/s10637-014-0120-7 Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6 – Reactivating Rb in cancer. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013; oral presentation PR02. Wiedemeyer, 2010, Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM, Proc Natl Acad Sci U S A, 107, 11501, 10.1073/pnas.1001613107 Katsumi, 2011, Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression, Biochem Biophys Res Commun, 413, 62, 10.1016/j.bbrc.2011.08.047 Konecny, 2011, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer, Clin Cancer Res, 17, 1591, 10.1158/1078-0432.CCR-10-2307 Dempsey, 2013, LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer, Cancer Research, AACR, 73 Sharpless, 2015, Forging a signature of in vivo senescence, Nat Rev Cancer, 15, 397, 10.1038/nrc3960 Anders, 2011, A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells, Cancer Cell, 20, 620, 10.1016/j.ccr.2011.10.001 Rader, 2013, Dual CDK4/CDK6 inhibition induces cell cycle arrest and senescence in neuroblastoma, Clin Cancer Res, 19, 6173, 10.1158/1078-0432.CCR-13-1675 Tate, 2014, Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts, Clin Cancer Res, 20, 3763, 10.1158/1078-0432.CCR-13-2846 Flaherty, 2012, Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer, Clin Cancer Res, 18, 568, 10.1158/1078-0432.CCR-11-0509 Leonard, 2012, Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma, Blood, 119, 4597, 10.1182/blood-2011-10-388298 DeMichele, 2013, A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer, J Clin Oncol, ASCO, 31 Dickson, 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma, J Clin Oncol, 31, 2024, 10.1200/JCO.2012.46.5476 Gopalan, 2014, A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A, J Clin Oncol, ASCO, 32 Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol, ASCO 2014;32:5s:suppl;poster 2528. Geoerger B, Bourdeaut F, DuBois SG, DeWire MD, Marabelle A, Pearson AD, et al. Phase I study of LEE011 (CDK4/6 inhibitor) in patients with malignant rhabdoid tumors, neuroblastoma, and cyclin D-CDK4/6 pathway-activated tumors. Annals Oncol 2014;25:suppl 4;poster 455P. Shapiro G, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol, ASCO 2013;31:suppl;oral presentation 2500. Goldman JW, Gandhi L, Patnaik A, Rosen LS, Hilton JF, Papadopoulos KP, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. J Clin Oncol, ASCO 2014;32:5s:suppl;poster 8026. Patnaik, 2014, Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer, Cancer Research, AACR, 74 Eli Lilly and Company. Lilly receives FDA breakthrough therapy designation for abemaciclib – a CDK 4 and 6 inhibitor – in advanced breast cancer. From: <https://investor.lilly.com/releasedetail.cfm?releaseid=935735>. Accessed January 2016. Thangavel, 2011, Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer, Endocr Relat Cancer, 18, 333, 10.1530/ERC-10-0262 Dickson, 1995, Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer, Cancer Lett, 90, 43, 10.1016/0304-3835(94)03676-A Gillett, 1994, Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining, Cancer Res, 54, 1812 O’Brien, 2014, In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer, Cancer Research, AACR, 74 Finn, 2014, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 16, 25, 10.1016/S1470-2045(14)71159-3 U.S. Food and Drug Administration. Palbociclib accelerated approval. From: <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm>. Accessed July 2015. ClinicalTrials.gov. From: <https://clinicaltrials.gov/>. Accessed January 2016. Turner, 2015, Palbociclib in hormone-receptor-positive advanced breast cancer, N Engl J Med, 373, 202, 10.1056/NEJMoa1505270 Munster P, Hamilton E, Estevez L, Boer R, Mayer I, Campone M, et al. Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2-breast cancer. J Clin Oncol, 2014 Breast Cancer Symposium; 32:suppl 26;poster 143. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. J Clin Oncol, ASCO 2014;32:5s:suppl;poster 534. Tolaney, 2015, A phase Ib study of abemaciclib with therapies for metastatic breast cancer, J Clin Oncol, ASCO, 33 Franco, 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer, Oncotarget, 5, 6512, 10.18632/oncotarget.2270 Gopalan, 2013, Inhibitory effect of the CDK4/6 inhibitor, PD 0332991, is enhanced by mTOR inhibition in non-small cell lung cancer (NSCLC), Cancer Research, AACR, 73 Juric D, Ismail-Khan R, Campone M, García-Estévez L, Becerra C, De Boer R, et al. Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2-breast cancer: safety, preliminary efficacy and molecular analysis. San Antonio Breast Cancer Symposium 2015;abstract P3–14-01. Bardia A, Modi S, Oliveira M, Campone M, Ma B, Dirix L, et al. Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer. San Antonio Breast Cancer Symposium 2015;abstract P6-13-01. Vora, 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors, Cancer Cell, 26, 136, 10.1016/j.ccr.2014.05.020 Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results. San Antonio Breast Cancer Symposium 2014;oral presentation S2-02. Spagnolo, 2015, BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies, Onco Targets Ther, 8, 157, 10.2147/OTT.S39096 Yadav, 2014, The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation, Mol Cancer Ther, 13, 2253, 10.1158/1535-7163.MCT-14-0257 Sosman, 2014, A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity, J Clin Oncol, ASCO, 32 Gogolin, 2013, CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage, Cell Cycle, 12, 1091, 10.4161/cc.24091 McClendon, 2012, CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy, Cell Cycle, 11, 2747, 10.4161/cc.21127 Clark, 2014, A phase I trial of palbociclib and paclitaxel in metastatic breast cancer, J Clin Oncol, ASCO, 32 Ogawa, 2013, Radiotherapy targeting cancer stem cells: current views and future perspectives, Anticancer Res, 33, 747 Horsley, 2008, NFATc1 balances quiescence and proliferation of skin stem cells, Cell, 132, 299, 10.1016/j.cell.2007.11.047 Laurenti, 2015, CDK6 levels regulate quiescence exit in human hematopoietic stem cells, Cell Stem Cell, 16, 302, 10.1016/j.stem.2015.01.017 Scheicher, 2015, CDK6 as a key regulator of hematopoietic and leukemic stem cell activation, Blood, 125, 90, 10.1182/blood-2014-06-584417 Robinson, 2013, RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs, PLoS One, 8, e78641, 10.1371/journal.pone.0078641 Shimura, 2012, Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells, Oncogenesis, 1, e12, 10.1038/oncsis.2012.12 Hagen, 2013, Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis, Cell Div, 8, 10, 10.1186/1747-1028-8-10 Han, 2013, A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy, Biochem Biophys Res Commun, 430, 1329, 10.1016/j.bbrc.2012.10.119 Zhang, 2014, Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo, Mol Cancer Ther, 13, 2184, 10.1158/1535-7163.MCT-14-0387 von Euw, 2014, Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma, Cancer Research, AACR, 74 DeMichele A. Palbociclib (PD-0332991) in breast cancer. 12th International Congress on Targeted Anticancer Therapies 2014;oral presentation O4.2. Geoerger B, Bourdeaut F, DuBois S, Fischer M, Geller J, Gottardo N, et al. Phase I study of the CDK4/6 inhibitor LEE011 in patients with malignant rhabdoid tumors or neuroblastoma. 46th Congress of the International Society of Paediatric Oncology 2014;oral presentation O-125.